Literature DB >> 7042172

Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

A K Pedersen, P Jakobsen, J P Kampmann, J M Hansen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7042172     DOI： 10.2165/00003088-198207010-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  56 in total

1.  Use of the newer uricosuric agents in the management of gout.

Authors:  J E SEEGMILLER; A I GRAYZEL
Journal:  JAMA       Date:  1960-07-09       Impact factor: 56.272

2.  A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671.

Authors:  J J BURNS; T F YU; A RITTERBAND; J M PEREL; A B GUTMAN; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1957-03       Impact factor: 4.030

3.  Sulphinpyrazone and warfarin: a probable drug interaction.

Authors:  A Gallus; D Birkett
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

4.  Biphasic sulphinpyrazone-warfarin interaction.

Authors:  G G Nenci; G Agnelli; M Berrettini
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-25

5.  Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.

Authors:  B Nunn; F J James
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

6.  Two metabolites of sulphinpyrazone and their identification and determination by mass spectrometry.

Authors:  P Jakobsen; A K Pedersen
Journal:  J Pharm Pharmacol       Date:  1981-02       Impact factor: 3.765

7.  Sulfinpyrazone kinetics after intravenous and oral administration.

Authors:  J B Lecaillon; C Souppart; J P Schoeller; G Humbert; P Massias
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

8.  Sulfinpyrazone in the prevention of sudden death after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1980-01-31       Impact factor: 91.245

9.  Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers.

Authors:  B Pfister; P Imhof; H Wirz
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

10.  Plasma levels and effects of sulfinpyrazone in patients requiring chronic hemodialysis.

Authors:  M M Bern; B M Cavaliere; G Lukas
Journal:  J Clin Pharmacol       Date:  1980 Feb-Mar       Impact factor: 3.126
View more
  4 in total

1.  Renal clearance of sulphinpyrazone in man.

Authors:  E G Lentjes; F G Russel; C A van Ginneken
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.

Authors:  B Rosenkranz; C Fischer; P Jakobsen; A Kirstein Pedersen; J C Frölich
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Pharmacokinetics and Reversible Biotransformation of Sulfinpyrazone and Its Metabolites in Rabbits. II. Multiple-Dose Study.

Authors:  B S Kuo; W A Ritschel
Journal:  Pharm Res       Date:  1986-06       Impact factor: 4.200
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.